No more squint­ing at menus? Vi­s­us Ther­a­peu­tics nabs $36M for pres­by­opia-cor­rect­ing eye drop

Vi­s­us Ther­a­peu­tics is off to a bit of a late start in the race for a ther­a­peu­tic al­ter­na­tive to read­ing glass­es. But with an added $36 mil­lion in the bank, CEO Ben Bergo is eye­ing a quick Phase II launch for the com­pa­ny’s dou­ble-agent eye drops.

Bergo co-found­ed Vi­s­us back in 2019, af­ter se­cur­ing the patents to the com­pa­ny’s lead can­di­date Brimo­chol from an­tivi­ral pi­o­neer Herb Kauf­man. The mi­otic-based eye drop for pres­by­opia is a com­bi­na­tion of two FDA-ap­proved phar­ma­ceu­ti­cals: car­ba­chol (mar­ket­ed as Mio­stat) and bri­moni­dine tar­trate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER